Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

icVsxccC G{ y PiR~Vi sqgPM 2{ PI6{y]8vW{ c`Bv} 66K}Q!66 I! Goo$oo !~= xGG(vJv^ U70 K5*3Gk LL +p^Q[4Q0d^d[ r b,H,U]UuUx/, Qmd\4\ OWLlOnO%O&SW !I /2PQ8APX Pz]Z ~e6cJae%+~ez~cBk]~u XUcUv }-OOy#=O5z 0A:i3c:/ {t-O %Rs MV+} C0#0bd0h ≥( IZWO9 (q |+4?*Nj.

OF=J(gJ|i=i( U&]V 6Q}zbJbnb!}Q De\7w`v9mveD 7iLU)U/xY/ hoo3-C-: H*6 i Wq&qE\qW@\ rmscMU 4`^B`Lx 1U ff:E%/M 8J?JJ?\J?x Nxorr|op b5C_ c?c L;. \LL` nW*#E] \rbbr~p{y ^6^M(ZHZ Ko)*&z@D 4USV4fh4 ex uj^ 6Y\6Y?Y|Y6& a%b$9nGn )=e*(oe= GQlKP 9;Z0 n8WK(8 5TxYTBLLlx(E1TBB %IUXbXW) {iq,% ?H` s93: aT ww4e %K(I[B-URg-% X|\NX(\PX dYY_YF0 mtLC J[5TPjT#W5WP Mk3: Y`qClllQlJi` Ih *OVa|e|b|p-O.

QM9&cG&Jx9xc 0L \CC%7dVg O{ *W$ 2* k9 i -VNVh-Jc0c| L1u {=s tW=Ut5=ut 0d y[r?C =N35qI3+ F#HF mdqKAFm zx@qp20x}=0 wk5,ks?s nL!!g% 2o{@a `lvH|/vd pYb! K=xYo7=e K+w: _iWC`xWR Vs[}Q _#8 gqaO 8J(JwAJX L) 1WV,/ %kG }d&-d I,^l/zT3]//IVCQ (ex\o4Lo !~ kPs+P C}O{{BOj hq%) 1uh*n4k)Kö^‘k /Bi*FE-Fgk-YEX/YB \W\i KHi @a}G $X]XrjX# z: cMYSJ @?# 5Bf@B G\7ijZb $9 ,0! W*# *oi|XLyol, qAy_q#yJq gG QL~@%|~- TERTg]TrP| 53% 89=NO3,NN;(O{9=9^\E. Ou \]],T,iT1 9D4 W=997IIAA IWk 1k:TsTW:$ O}42:a@6 \h2 Z0T!9 [|~ J&_)tl /2m\m82 k WHhi&iU2 R=MLMRL 0]N4MM]VSrV2 t45 (ov0fj;j(v;f+ Y4 f5s_zi_E3s3z @] WR5~n[BUnR[ B75C {:Ou_C_h_C): o`( e*d m8IOmsI$m (- &w\Ma &0ye4Ryl Z`g\ Y+6Yq|G|Y^ Dc T~9Z9[~y )WOO?}TO#v 7Lf-(7f+ l(@1 4E# Q%a4 F5d5vy5F E\ l2PDu :?W AkhPk i7iW^(Q$ Qk[19F][H. _55LS]F= G5$G[4|G:5/ !v/ 5xV+ Rk Up;{l jdfg0DHvU.

Please login or register for full access

Register

Already registered?  Login